Peer review reports
From: PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
Original Submission | ||
---|---|---|
16 Mar 2011 | Submitted | Original manuscript |
28 Mar 2011 | Author responded | Author comments - Xi-Chun Hu |
Resubmission - Version 2 | ||
28 Mar 2011 | Submitted | Manuscript version 2 |
13 Apr 2011 | Reviewed | Reviewer Report - Maurizio Scaltriti |
21 Apr 2011 | Reviewed | Reviewer Report - Katherine Hale |
20 May 2011 | Author responded | Author comments - Xi-Chun Hu |
Resubmission - Version 3 | ||
20 May 2011 | Submitted | Manuscript version 3 |
10 Jun 2011 | Author responded | Author comments - Xi-Chun Hu |
Resubmission - Version 4 | ||
10 Jun 2011 | Submitted | Manuscript version 4 |
Publishing | ||
15 Jun 2011 | Editorially accepted | |
15 Jun 2011 | Article published | 10.1186/1471-2407-11-248 |